乙型肝炎病毒基因突变与临床疾病进展的关系

doi:10.3969/j.issn.1672-5069.2014.02.028

Abstract

Li Fan, Chen Guofeng，Xu Dongping.. Hepatitis B viral gene mutation and disease progression in patients with hepatitis B virus infection[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2014, 17(2): 210-213.

[1] 徐春利，郝友华，杨东亮. 影响慢性乙型肝炎病毒感染者临床结局的病毒学因素研究进展. 实用肝脏病杂志，2012，25（3）:270-272.
[2] Chen MT，Billaud JN，Sallberg M，et al. A function of the hepatitis B virus precore protein is to regulate the immune response to the core antigen. Proc Natl Acad Sci U S A，2004，101（41）:14913-14918.
[3] Tong S，Kim KH，Chante C，et al. Hepatitis B virus e antigen variants. Int J Med Sci，2005，2（1）:2-7.
[4] Baumert TF，Yang C，Schurmann P，et al. Hepatitis B virus mutations associated with fulminant hepatitis induce apoptosis in primary Tupaia hepatocytes. Hepatology，2005，41（2）:247-256.
[5] Sugiyama M，Tanaka Y，Kurbanov F，et al. Influences on hepatitis B virus replication by a naturally occurring mutation in the core gene. Virology，2007，365（2）:285-291.
[6] Kao JH，Chen PJ，Lai MY，et al. Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology，2003，124（2）:327-334.
[7] Lin CL，Liao LY，Wang CS，et al. Basal core-promoter mutant of hepatitis B virus and progression of liver disease in hepatitis B e antigen-negative chronic hepatitis B. Liver Int，2005，25（3）:564-570.
[8] Chen BF，Liu CJ，Jow GM，et al. High prevalence and mapping of pre-S deletion in hepatitis B virus carriers with progressive liver diseases. Gastroenterology，2006，130（4）:1153-1168.
[9] Liu CJ，Chen BF，Chen PJ，et al. Role of hepatitis B viral load and basal core promoter mutation in hepatocellular carcinoma in hepatitis B carriers. J Infect Dis，2006，193（9）:1258-1265.
[10] Tong MJ，Blatt LM，Kao JH，et al. Precore/basal core promoter mutants and hepatitis B viral DNA levels as predictors for liver deaths and hepatocellular carcinoma. World J Gastroenterol，2006，12（41）:6620-6626.
[11] Liu S，Zhang H，Gu C，et al. Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma:a meta-analysis. J Natl Cancer Inst，2009，101（15）:1066-1082.
[12] Guo X，Jin Y，Qian G，et al. Sequential accumulation of the mutations in core promoter of hepatitis B virus is associated with the development of hepatocellular carcinoma in Qidong，China. J Hepatol，2008，49（5）:718-725.
[13] Yin J，Xie J，Liu S，et al. Association between the various mutations in viral core promoter region to different stages of hepatitis B，ranging of asymptomatic carrier state to hepatocellular carcinoma. Am J Gastroenterol，2011，106（1）:81-92.
[14] Xu Z，Ren X，Liu Y，et al. Association of hepatitis B virus mutations in basal core promoter and precore regions with severity of liver disease:an investigation of 793 Chinese patients with mild and severe chronic hepatitis B and acute-on-chronic liver failure. J Gastroenterol，2011，46（3）:391-400.
[15] Chen CH，Hung CH，Lee CM，et al. Pre-S deletion and complex mutations of hepatitis B virus related to advanced liver disease in HBeAg-negative patients. Gastroenterology，2007，133（5）:1466-1474.
[16] Kim H，Lee SA，Kim DW，et al. Naturally occurring mutations in large surface genes related to occult infection of hepatitis B virus genotype C. Plos One，2013，8（1）:e54486.
[17] Hsieh YH，Su IJ，Wang HC，et al. Pre-S mutant surface antigens in chronic hepatitis B virus infection induce oxidative stress and DNA damage. Carcinogenesis，2004，25（10）:2023-2032.
[18] Wang HC，Chang WT，Chang WW，et al. Hepatitis B virus pre-S2 mutant upregulates cyclin A expression and induces nodular proliferation of hepatocytes. Hepatology，2005，41（4）:761-770.
[19] Hsieh YH，Su IJ，Wang HC，et al. Hepatitis B virus pre-S2 mutant surface antigen induces degradation of cyclin-dependent kinase inhibitor p27Kip1 through c-Jun activation domain-binding protein 1. Mol Cancer Res，2007，5（10）:1063-1072.
[20] Mun HS，Lee SA，Kim H，et al. Novel F141L pre-S2 mutation in hepatitis B virus increases the risk of hepatocellular carcinoma in patients with chronic genotype C infections. J Virol，2011，85（1）:123-132.
[21] Lin CL，Liu CH，Chen W，et al. Association of pre-S deletion mutant of hepatitis B virus with risk of hepatocellular carcinoma. J Gastroenterol Hepatol，2007，22（7）:1098-1103.
[22] Yeung P，Wong DK，Lai CL，et al. Association of hepatitis B virus pre-S deletions with the development of hepatocellular carcinoma in chronic hepatitis B. J Infect Dis，2011，203（5）:646-654.
[23] Wang HC，Huang W，Lai MD，et al. Hepatitis B virus pre-S mutants，endoplasmic reticulum stress and hepatocarcinogenesis. Cancer Sci，2006，97（8）:683-688.
[24] Mun HS，Lee SA，Jee Y，et al. The prevalence of hepatitis B virus preS deletions occurring naturally in Korean patients infected chronically with genotype C. J Med Virol，2008，80（7）:1189-1194.
[25] Song BC，Kim H，Kim SH，et al. Comparison of full length sequences of hepatitis B virus isolates in hepatocellular carcinoma patients and asymptomatic carriers of Korea. J Med Virol，2005，75（1）:13-19.
[26] Ahn SH，Yuen L，Han KH，et al. Molecular and clinical characteristics of hepatitis B virus in Korea. J Med Virol，2010，82（7）:1126-1134.
[27] Yin J，Xie J，Zhang H，et al. Significant association of different preS mutations with hepatitis B-related cirrhosis or hepatocellular carcinoma. J Gastroenterol，2010，45（10）: 1063-1071.
[28] Ji D，Liu Y，Li L，et al. The rtL229 substitutions in the reverse transcriptase region of hepatitis B virus （HBV） polymerase are potentially associated with lamivudine resistance as a compensatory mutation. J Clin Virol，2012，54（1）:66-72.
[29] Locarnini SA，Yuen L. Molecular genesis of drug-resistant and vaccine-escape HBV mutants. Antivir Ther，2010，15（3 Pt B）:451-461.
[30] Yeh CT，Chen T，Hsu CW，et al. Emergence of the rtA181T/sW172* mutant increased the risk of hepatoma occurrence in patients with lamivudine-resistant chronic hepatitis B. BMC Cancer，2011，11: 398.
[31] Dai J，Chen EQ，Bai L，et al. Biological characteristics of the rtA181T/sW172* mutant strain of hepatitis B virus in animal model. Virol J，2012，9:280.
[32] Preikschat P，Gunther S，Reinhold S，et al. Complex HBV populations with mutations in core promoter，C gene，and pre-S region are associated with development of cirrhosis in long-term renal transplant recipients. Hepatology，2002，35（2）:466-477.
[33] Liu S，Xie J，Yin J，et al. A matched case-control study of hepatitis B virus mutations in the preS and core promoter regions associated independently with hepatocellular carcinoma. J Med Virol，2011，83（1）:45-53.
[34] Lee MH，Kim do Y，Kim JK，et al. Combination of preS deletions and A1762T/G1764A mutations in HBV subgenotype C2 increases the risk of developing HCC. Intervirology，2012，55（4）:296-302.

Hepatitis B viral gene mutation and disease progression in patients with hepatitis B virus infection

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	chronic hepatitis B Zhu Lingyun, Zhang Maohai Cui Shasha, et al.. Serum IL-12 and IL-18 levels as well as peripheral blood mononuclear cell FOXp3 in patients with [J]. Journal of Practical Hepatology, 2019, 22(6): 816-819.
[2]	Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 820-823.
[3]	Min Feng, Huang Wenqi, Wu Weibing, et al.. Implications of serum adipocytokine levels in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 824-827.
[4]	patients with chronic hepatitis B Zhang Yingming, Shen Shuang, Tian Fei, et al.. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in [J]. Journal of Practical Hepatology, 2019, 22(6): 828-831.
[5]	chronic hepatitis B virus carriers Wu Haiyi, Chen Jianxin.. Diagnostic efficacy of four non-invasive diagnostic models in evaluating significant liver fibrosis in [J]. Journal of Practical Hepatology, 2019, 22(6): 832-835.
[6]	Ma Liying, Shen Lijuan.. Efficacy and safety of tenofovir in the treatment of pregnant women with high HBV DNA loads [J]. Journal of Practical Hepatology, 2019, 22(6): 836-839.
[7]	Li Chuanjie, Xu Jing, Wang Liangliang, et al.. Changes of serum HBsAg levels in patients with chronic hepatitis B receiving entecavir treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 928-929.
[8]	Du Keye, Yang Dongliang, Liu Jia. Regulatory T cells in hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 613-616.
[9]	Liao Guichan, Peng Jie, Zhang Xiaoyong. Roles of hepatocytes in intrinsic innate immunity in control of hepatits B virus infection [J]. Journal of Practical Hepatology, 2019, 22(5): 617-619.
[10]	Zhao Xieshan, Wu Chunrong, Wang Chunfeng, et al. Preliminary study on the efficacy of combination of tenofovir and Anluo Huaxian pill in the treatment of patients with HBeAg-negative chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 644-647.
[11]	Tu Jiexia, Wang An’na, Liao Ruoxi. Comparative study of interferon alpha -2b and peginterferon alpha -2a in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 648-651.
[12]	Gao Wei, Hou Yong. Diagnostic efficacy of hepatic fibrosis by liver stiffness measurement in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 652-655.
[13]	Zhu Yucheng, Yan Jiawei, Sun Jingkun, et al. Serum diamine oxidase level in patients with hepatitis B-induced acute-on-chronic liver failure [J]. Journal of Practical Hepatology, 2019, 22(5): 672-675.
[14]	Zhang Mei, Shi Xiuying, Li Linjuan, et al. Hepatic expression of interferon inducible protein -10 in patients with hepatitis B liver cirrhosis and hepatogenic diabetes mellitus [J]. Journal of Practical Hepatology, 2019, 22(5): 688-691.
[15]	Bai Yichun, Deng Jihong, Mei Xiaoping. Efficacy of peginterferon alfa-2b treatment and affecting response factors in patients with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 490-493.